COMPRITOL® 888 LIPID MATRIX VIA TWIN SCREW EXTRUDER

  • Abishek Wadhwa Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 576104
  • Vashish Mathura Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 576104
  • Mahalaxmi Rathnanand Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 576104
  • Anup Naha Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 576104
  • Shaila Angela Lewis Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, India 576104

Abstract

Objective: The objective of this research was to explore the potential of Hot Melt Extrusion (HME) technique by using theophylline as the model drug to produce sustained release tablets utilizing Compritol®888 ATO as the retarding material and to study the influence of lipid: excipient ratio, excipient type as well as the processing conditions of the extruder on the release profile.

Methods: The tablets prepared using hot fusion method was compared to the ones concocted by the HME technology. During the HME process, a powder mixture of moisture-free drug, lipid, and other adjuncts was introduced into the extruder and liquefied inside the barrel of the extruder. The in vitro dissolution studies of the formulations were carried out in pH 7.2 buffer using USP Apparatus 2. The extrudates were characterized via differential scanning calorimetry.

Results: Comparing the two methods of processing, it was observed by the dissolution studies using phosphate buffer pH 7.2, that the tablets prepared by Hot Melt Extrusion method had a higher extent of release where all 3 formulations crossed 80% at the 8-hour mark, whereas the tablets prepared by hot fusion method did not show such consistency.

Conclusion: This study demonstrated the fact that Compritol®888 ATO is a suitable waxy material that can be used as a matrix-forming agent to control the release of theophylline using the Hot Melt Extrusion process.

Keywords: Theophylline, Hot-melt extrusion, Compritol®888 ATO, Sustained-release tablets, lipid matrix

References

1. Piafsky KM, Ogilvie RI. Dosage of theophylline in bronchial asthma. N Engl J Med 1975;292:1218–22.
2. Ziad Hussein, Michael Friedman. Release and absorption characteristics of novel theophylline sustained-release formulations: in vitro-in vivo correlation. Pharm Res 1990; 7:1167–71.
3. Khatavkar UN, Kumar KJ, Shimpi SL. Novel approaches for the development of oral controlled release compositions of galantamine hydrobromide and paroxetine hydrochloride hemihydrate: a review. Int J Appl Pharm 2016;8:1-6.
4. Hayashi T, Kanbe H, Okada M, Suzuki M, Ikeda Y, Onuki Y, et al. Formulation study and drug release mechanism of a new theophylline sustained-release preparation. Int J Pharm 2005;304:91–101.
5. Gaurav Agarwal, Shilpi Agarwal PK SG. Oral sustained-release tablets: an overview with a special emphasis on matrix tablet. Am J Adv Drug Delivery 2017;304:64–76.
6. Almeida H, Amaral MH, Lobao P. Comparative study of sustained-release lipid microparticles and solid dispersions containing ibuprofen. Brazilian J Pharm Sci 2012;48:529–36.
7. Barthelemy P, Laforet JP, Farah N, Joachim J. Compritol®l888 ATO ATO: an innovative hot-melt coating agent for prolonged-release drug formulations. Eur J Pharm Biopharm 1999;47:87–90.
8. Saraiya D, Bolton S. The use of precirol® to prepare sustained-release tablets of theophylline and quinidine gluconate. Drug Dev Ind Pharm 1990;16:1963–9.
9. Hamdani J, Moes AJ, Amighi K. Physical and thermal characterisation of precirol and compritol as lipophilic glycerides used for the preparation of controlled-release matrix pellets. Int J Pharm 2003;260:47–57.
10. Obaidat, Rana, Bashar Al-taani, Hanan Al-quraan. Effect of selected polymers on dissolution and stabilization of amorphous form of meloxicam. Int J Pharm Pharm Sci 2017;9:33-42.
11. Padsalgi, Amol, Sanjay Bidkar, Vijay Jadhav DS. Sustained release tablet of theophylline by hot melt wax coating. Asian J Pharm 2008;2:26–9.
12. Aitken Nichol C, Zhang F, McGinity JW. Hot melt extrusion of acrylic films. Pharm Res 1996;13:804–8.
13. Desai, Sanjeevani, John Disouza, Kiran Musle, Hoshmani Avinash. Solubility enhancement of ritonavir by hot melt extrusion. Int J Pharm Pharm Sci 2016;8:309-12.
14. Patil H, Tiwari RV, Repka MA. Hot-melt extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech 2016;17:20–42.
15. Zhang J, Feng X, Patil H, Tiwari RV, Repka MA. Coupling 3D printing with hot-melt extrusion to produce controlled-release tablets. Int J Pharm 2017;519:186–97.
16. Pather SI, Russell I, Syce JA, Neau SH. Sustained release theophylline tablets by direct compression. Int J Pharm 1998;164:1–10.
17. Nakano M, Ohmori N, Ogata A, Sugimoto K, Tobino Y, Iwaoku R, et al. Sustained release of theophylline from hydroxypropylcellulose tablets. J Pharm Sci 1983;72:378–80.
18. Rey H, Wagner KG, Wehrle P, Schmidt PC. Development of matrix-based theophylline sustained-release micro tablets. Drug Dev Ind Pharm 2000;26:21–6.
19. Patel R, Baria A. Formulation development and process optimization of theophylline sustained release matrix tablet. Int J Pharm Pharm Sci 2009;61:30-42.
Statistics
248 Views | 114 Downloads
How to Cite
Wadhwa, A., Mathura, V., Rathnanand, M., Naha, A., & Lewis, S. A. (2019). COMPRITOL® 888 LIPID MATRIX VIA TWIN SCREW EXTRUDER. International Journal of Applied Pharmaceutics, 11(1), 261-264. https://doi.org/10.22159/ijap.2019v11i1.29675
Section
Short Communication(s)